Alkermes Plc at Piper Sandler Healthcare Conference Transcript

Nov 28, 2023 / 04:00PM GMT
David A. Amsellem - Piper Sandler & Co., Research Division - MD & Senior Research Analyst

Okay. Good morning. Thanks, everyone, for joining us at the 35th Annual Piper Sandler Healthcare Conference. I'm David Amsellem from the pharma team. And with us is Alkermes and joining us the CEO, Richard Pops. Delighted to have you with us. And lots to talk about. So I know everyone wants to talk about our favorite topic, orexin agonist 2680. I am not going to start with that; however, we'll start with a high-level question, if that's okay. Since you completed the separation of the oncology business.

Questions and Answers:

David A. Amsellem - Piper Sandler & Co., Research Division - MD & Senior Research Analyst

I'm particularly interested in now, how are you thinking about the neuroscience business, the stand-alone Neuroscience business, particularly the cost structure, your margins and, ultimately, your strategic vision for that business over the long term.

Richard F. Pops - Alkermes plc - Chairman & CEO
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot